European Companies Search Engine
EU funding (€598,500): Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications Hor1 Dec 2017 EU Research and Innovation programme "Horizon"
Text
Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications
Nanotechnology has received widespread attention in the last several decades due to the technological breakthroughs it has enabled across sectors from electronics to medicine. Towards the great challenges that nanotechnology arise, Nano-OligoMed has the ambition to establish and support a network of international collaboration, enabling a collaborative scientific team to effectively use a diversity of approaches and strategies to generate and test hybrid nanomaterials for the efficient and safe systemic delivery of oligonucleotide-based therapeutic agents. To this end, we have set-up a joint multidisciplinary scientific collaborative programme that through exchange, international mobility, and strongly collaborative transfer of knowledge and training activities between 4 European and 3 extra-European countries, will bring together leading experts under the field of “nanomaterials in biomedicine”. The scientific aim of Nano-OligoMed is the creation of degradable hybrid structures that combine the rigid, inert silica with the delicate programmable oligonucleotides or artificial oligonucleotide-mimics. The possibility to develop novel oligonucleotide-based materials will enable a) the degradation of the drug carrier at the presence of a specific input as a function of the intrinsic bio-responsive feature of oligonucleotides, b) the activation of a therapeutic function as a result of the bio-molecular interaction between the oligonucleotide-based material and the molecular target (i.e. miRNAs) and c) the delivery of the chemical payload (DNA and/or artificial mimics, even in combination with cancer drugs) upon cell internalization. The international academic networking, the broadening of the research skills, the educational activities, will provide to young (PhD students) and senior scientists, specific competences in the field of materials sciences, nanotechnology, molecular biology and molecular medicine.
Funded Companies:
| Company name | Funding amount |
| Royal Institution FOR THE Advancement OF Learning Mcgill University | ? |
| Nanomol Technologies SL | €126,000 |
| Universita Degli Studi Di Milano | €67,500 |
| Universita Degli Studi Di Parma | €121,500 |
| Universita Degli Studi Di Roma TOR Vergata | €162,000 |
| Universite de Strasbourg | €121,500 |
Source: https://cordis.europa.eu/project/id/778133
The filing refers to a past date, and does not necessarily reflect the current state. The current state is available on the following page: Royal Institution FOR THE Advancement OF Learning Mcgill University, Montreal, Canada.
The visualizations for "Royal Institution FOR THE Advancement OF Learning Mcgill University - EU funding (€598,500): Hybrid Nanostructured Oligonucleotide Platforms for Biomedical Applications"
are provided by
North Data
and may be reused under the terms of the
Creative Commons CC-BY license.
